Theradiag – i-Tracker: High performance TDM assays for biologics

Last updated: 24th June, 2024

Therapeutic Drug Monitoring (TDM) of biologics entails measuring drug and anti-drug antibody concentrations, with subsequent possible dose adjustment to ensure optimised dosing for the patient.

With their high performance and short turnaround time, i-Tracker CLIA kits, in combination with the i-Track random-access analyser, enable the clinician to make therapeutic decisions promptly.

In giving access to rapid treatment adjustments, i-Tracker assays contribute to improve overall clinical outcomes for the patients while minimising the cost of treatment.

  • Innovative CLIA technology
  • Short turnaround time
  • Validated on princeps and biosimilars
  • Calibrated against WHO international standards


Interpret dosing information

  • Drug levels required to improve clinical outcomes may vary between patients and depend on the desired therapeutic endpoint.
  • ​​​​​In patients with undetectable drug levels, anti-drug antibody (ADAb) quantification helps to identify how to improve patient response.
  • In patients considered to be good responders with higher drug trough levels, dose escalation may be possible without affecting clinical outcomes.
  • In patients with high anti-drug antibody levels, a switch in class may be necessary.
  • In patients with low anti-drug antibody levels, the addition of an immunosuppressive drug may improve clinical outcomes.

Ex​​​​​​ample of therapeutic decision algorithm in patients with loss of response:

  Negative Anti-drug Antibodies Positive Anti-drug Antibodies
Therapeutic level of Drug Switch out of
therapeutic class
Retest
Subtherapeutic level of Drug Treatment optimisation Switch in- [therapeutic] class

 


Learn about Theradiag i-Tracker TDM assays

Download brochure >

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.

Go BackGo Back
Top